GRFS
GRIFOLSยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
GRFS Profile
Grifols, S.A.
The Europe's largest plasma products company
Biological Technology
--
06/02/2011
NASDAQ Stock Exchange
23,822
12-31
Depository Receipts (Ordinary Shares)
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles 08174, Barcelona, Spain
--
GRIFOLS, S.A. is a global healthcare company with products sold in more than 100 countries and directly affiliated institutions in more than 30 countries. The company's Class A shares have been listed on the Spanish Stock Exchange (MCE: GRF) since 2006 and became a constituent of the IBEX 35 Index in 2008. In 2011, the company issued non-voting Class B shares through American Depositary Receipts (ADRs) on the Spanish Stock Exchange (MCE: GRF.P) and Nasdaq (GRFS) in the United States. Griffalls has become one of the largest plasma companies in the world and has expanded and diversified its plasma sources in recent years by establishing a strong network of plasma donation centers in the United States, Europe, Egypt and Canada. Griffiles uses the acquired plasma to produce important drugs for the treatment of chronic, rare and some very serious diseases. As a recognized leader in the field of blood transfusion medicine, the company has a comprehensive portfolio of solutions designed to improve safety from blood donation to blood transfusion. In addition, the company supplies biological products for non-therapeutic uses. Grifols has the necessary infrastructure and experience to plan for future needs and maintain sustainability through continuous improvement and process and cost optimization. Its strong production bases, mainly located in the United States and Spain, enable it to expand its large-scale, global business and meet the growing market demand.
